Colesevelam as Add-on to Pioglitazone Therapy for Type 2 Diabetes Mellitus
A Randomized, Double-Blind, Placebo Controlled, Parallel Group Study of the Efficacy and Safety of WELCHOL as Add-on to Pioglitazone Therapy for Type 2 Diabetes Mellitus (T2DM)
Sponsor: Daiichi Sankyo
This PHASE3 trial investigates Type 2 Diabetes Mellitus and is currently completed. Daiichi Sankyo leads this study, which shows 13 recorded versions since 2009 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
13 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Mar 2024 — Jul 2024 [monthly]
Completed PHASE3
-
Jan 2023 — Mar 2024 [monthly]
Completed PHASE3
▶ Show 8 earlier versions
-
Dec 2022 — Jan 2023 [monthly]
Completed PHASE3
-
Jan 2021 — Dec 2022 [monthly]
Completed PHASE3
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE3
-
Sep 2017 — Jun 2018 [monthly]
Completed PHASE3
-
Aug 2017 — Sep 2017 [monthly]
Completed PHASE3
-
May 2017 — Aug 2017 [monthly]
Completed PHASE3
-
Feb 2017 — May 2017 [monthly]
Completed PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE3
First recorded
Apr 2009
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Daiichi Sankyo
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Alexandria, United States , Arlington, United States , Arlington Heights, United States , Belvidere, United States , Berlin, United States , Billings, United States , Birmingham, United States , Bloomington, United States , Brooklyn Center, United States , Buena Park, United States and 105 more locations